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Durability of thoracoabdominal aortic aneurysm
repair in patients with connective tissue disorders
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Objective: Thoracoabdominal aortic aneurysm (TAAA) repair is a durable procedure performed with reasonable
perioperative mortality and morbidity in patients with atherosclerotic aortic disease. However, the long-term outcome
and durability of TAAA repair performed in patients with a connective tissue disorder (CTD) is not well known.
Methods: The records of 257 patients who underwent TAAA repair at the Johns Hopkins Hospital between January 1992
and December 2001 were reviewed. Survival analysis was performed with Kaplan-Meier analysis, and subgroups were
compared with the log-rank test. Multivariable analysis was performed with the Cox proportional hazards model and
logistic regression.
Results: Patients with CTD (n 31) were seen earlier (mean age, 48.6 2.9 years) than patients without CTD (mean age,
69.1 0.6 years; P < .0001, Mann-Whitney U test) and had a greater incidence rate of aortic dissection (52% versus 19%;
P < .0001, 2 test) and extent I or II aneurysm (77% versus 64%; P .04). The perioperative (30-day) mortality rate was
6.5% in patients with CTD, which was similar to the rest of the cohort (P  .39, Fisher exact test). The incidence rate of
paraparesis/paraplegia was 12.9%/6.5% in patients with CTD, and CTD was the only factor predictive of paraparesis
(P .03; odds ratio, 9.3; logistic regression). The cumulative survival rate among the entire cohort was 53.4% 4.4% at
5 years (Kaplan-Meier), and no difference was seen among patients with or without CTD (P  .16, log-rank test) or
among different Crawford extents (P .29). Of the two late (>6 months) deaths in patients with CTD, none were from
aortic rupture or dissection, compared with two of 31 late deaths in patients without CTD. Multivariable analysis
confirmed that postoperative renal failure (P .03) predicted mortality but neither CTD (P .93), nor Crawford extent
(P .21, Cox regression) predicted mortality. Among survivors, no mean difference was found in largest aortic diameter
on follow-up imaging in patients with or without CTD (4.7  0.3 cm versus 4.4  0.3 cm; P  .47, Mann-Whitney U
test). The cumulative graft patency rate, representing long-term graft stability and with death, rupture, dissection, or
recurrent aneurysm as endpoints, was 47.5% 4.6% at 5 years (Kaplan-Meier) and was similar in patients with or without
CTD (P  .10, log-rank test).
Conclusion: TAAA repair appears to be a durable operation, with a reasonable 5-year patient survival rate and a low risk
of postoperative paraplegia or additional aortic events. Patients with CTD can expect their outcome, including long-term
survival and aortic stability, to be similar to patients without CTD. (J Vasc Surg 2002;36:696-703.)
Thoracoabdominal aortic aneurysm (TAAA) repair is a
durable procedure performed with acceptable perioperative
mortality and morbidity in patients with atherosclerotic
aortic disease.1 The long-term outcome of TAAA repair
likewise is good, with approximately 50% to 60% cumula-
tive 5-year survival rates in several series.2-7
The connective tissue disorders (CTDs) are a diverse
group of syndromes with defects in connective tissue struc-
tural integrity; vascular wall weakness is common to all
these syndromes. The most common CTD is Marfan syn-
drome, an autosomal dominant disorder characterized by
defective fibrillin, a structural component of microfibrils,
and manifested clinically by characteristic skeletal, ocular,
and cardiovascular defects.8-12 Mortality in untreated pa-
tients with CTD such as Marfan syndrome is usually the
result of cardiovascular disease, most commonly rupture of
the aorta.13-15 Replacement of a dilated aortic annulus and
ascending aorta has been shown to significantly prolong the
life expectancy of patients with Marfan syndrome.12,16-20
In addition, the need for ascending aortic replacement in
patients with Marfan syndrome predicts the development
of a large TAAA necessitating repair.17,19-21
However, the long-term outcome and durability of
TAAA repair performed in patients with CTD is not well
known. This study reports the outcome after TAAA repair
in patients with CTD compared with those patients with-
out CTD.
METHODS
The records of all patients who underwent repair of a
TAAA at the Johns Hopkins Hospital between January
1992 and December 2001 were reviewed retrospectively.
Patients without an aneurysm but with a similar thoraco-
abdominal operative procedure, such as those patients with
aortic dissection, and patients with purely thoracic aneu-
rysms were excluded from this analysis.
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Patients with CTD were previously known and identi-
fied either with genetic testing for Marfan (n 22) or Ehlers-
Danlos (n  3) syndromes or with a strong family history of
Marfan syndrome and a Marfanoid appearance (n 6). Rou-
tine preoperative screening for CTD was not performed.
Patients were considered before surgery to have renal
insufficiency if the serum creatinine level (Cr) was 1.8 or
more and 2.4 or less, and renal failure if the Cr was 2.5 or
more. Patients were considered to have postoperative renal
failure if the Cr either doubled from its baseline value or was
3.0 or more at discharge from the hospital.5
TAAA repair was performed with distal aortic perfusion
and sequential aortic clamping.1 Spinal arteries identified
on preoperative arteriography were routinely reimplanted
intraoperatively. Lumbar drains were routinely placed be-
fore elective surgery and cerebrospinal fluid (CSF) drainage
began in the operating room and continued for 3 days after
surgery.22 Spinal cooling or instillation of pharmacologic
agents was not performed in any patient. Patients with TAAA
and concomitant aortic dissection had adjunctive aortic fenes-
tration or tailoring procedures performed only in small sec-
tions of the aortas not needing graft repair of an aneurysm.23
Routine follow-up imaging for patients after TAAA
repair included yearly computed tomographic (CT) scans
with three-dimensional reconstruction. Development of
additional aneurysms in areas of the aorta that were not
initially repaired prompted close observation and possibly
surgical repair, on the basis of standard criteria.1,2
Comparison between groups was performed with the
Mann-Whitney U test for nonparametric variables and the
2 test or Fisher exact test for categorical variables. Survival
analysis was performed with Kaplan-Meier analysis, and
subgroups were compared with the log-rank or Breslow-
Gehan-Wilcoxon tests. Freedom from additional aortic
events was calculated as cumulative graft patency with
Kaplan-Meier analysis and with death, aortic or graft rup-
ture, aortic dissection, or recurrent aneurysm as endpoints.
Multivariable analysis was performed with the Cox propor-
tional hazards model and logistic regression. P values were
considered significant at .05 or less.
RESULTS
During this study, 257 patients underwent TAAA re-
pair at the Johns Hopkins Hospital. Of these 257 patients,
158 were men and 99 were women; demographics are
presented in Table I. The mean size of the thoracic aorta
was 6.7 0.1 cm, and the mean size of the abdominal aorta
was 5.5  0.2 cm. Twenty-two patients (9%) had previous
thoracic segment repairs, and 53 (21%) had prior abdomi-
nal repairs.
Patients with CTD (n  31) most commonly had
Marfan syndrome (Table I). Fourteen patients (45%) had
prior surgical repair of the ascending aorta, including eight
(26%) with elephant trunk procedures.24 These patients
were seen earlier (mean age, 48.6 2.9 years) than patients
without CTD (mean age, 69.1  0.6 years; P  .0001,
Mann-Whitney U test) and had a greater incidence rate of
aortic dissection (52% versus 19%; P  .0001, 2 test).
Eight extent I (26%), 16 extent II (52%), five extent III
(16%), and two (6%) extent IV aneurysms were seen, which
was a more heavily weighted distribution of extent I and II
aneurysms (77% versus 64%) than in the rest of the study
Table I. Demographics of patients who underwent TAAA repair at Johns Hopkins Hospital from 1992 to 2001
Whole group CTD No CTD P value
No. 257 31 (12%) 226 (88%)
Age (mean  SEM; y) 66.6  0.8 48.6  2.9 69.1  0.6 .0001
Male 158 (61%) 22 (71%) 136 (60%) .25
White 210 (82%) 29 (94%) 181 (80%) .08
Smoking history 193 (75%) 18 (58%) 175 (77%) .02
Hypertension 227 (88%) 27 (87%) 200 (88%) .77
Diabetes 18 (7%) 2 (6%) 16 (7%) .99
Coronary artery disease 119 (46%) 12 (39%) 107 (47%) .37
Peripheral vascular disease 87 (34%) 12 (39%) 75 (33%) .58
COPD 57 (22%) 3 (10%) 54 (24%) .10
Preoperative renal insufficiency
Chronic renal insufficiency
(1.8  Cr  2.4)
20 (8%) 1 (3%) 19 (8%) .70
Chronic renal failure (Cr  2.5) 10 (4%) 1 (3%) 9 (4%) .99
CTD 31 (12%) 31 0
Marfan syndrome 28 (90%) 28 (90%) 0
Ehlers-Danlos syndrome 3 (10%) 3 (10%) 0
Crawford extent
I 91 (35%) 8 (26%) 83 (37%)
II 77 (30%) 16 (52%) 61 (27%)
III 71 (28%) 5 (16%) 66 (29%)
IV 18 (7%) 2 (6%) 16 (7%)
Previous aortic dissection 60 (23%) 16 (52%) 44 (19%) .0001
Emergent presentation/rupture 17 (7%) 2 (6%) 15 (7%) .99
SEM, Standard error of mean; COPD, chronic obstructive pulmonary disease.
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group (P .04, 2 test). No difference was found in mean
aneurysm size in patients with CTD compared with pa-
tients without CTD (thoracic size, 6.7  0.3 cm versus
6.7  0.1 cm; P  .65, Mann-Whitney U test). Patients
with CTD had a similar rate of ruptured TAAA as patients
without CTD (6.5% versus 6.6%; P  .99, Fisher exact
test).
Among the entire patient group, preoperative spinal
arteriography was successfully performed in 191 patients
(74%), and a spinal artery was identified in 86 of these cases
(45%). Twenty of 31 patients (65%) with CTD successfully
underwent arteriography, which was statistically similar to
the rate of arteriography in patients without CTD (P .38,
2 test). Spinal artery identification was successful in seven
of these 20 patients (35%), which was not statistically
different than the rate of success in patients without CTD
(P  .25, 2 test).
Lumbar drains were used in 168 patients (65%), includ-
ing 22 of the 31 patients with CTD (71%), which was not
different than the usage in patients without CTD (P .48,
2 test). Drains were usually removed on postoperative day
3 (mean, 2.4 0.1 days) and removed a mean of 367 22
mL of CSF. No difference was seen in the amount of CSF
removed in patients with (408  82 mL) or without
(361  23 mL) CTD (P  .98, Mann-Whitney U test).
Aortic fenestration was used as an adjunctive procedure
in 13 patients, 10 without CTD (4%) and three with CTD
(10%; P  .20, Fisher exact Test). Aortic tailoring was also
performed in 17 patients, more frequently in patients with
CTD (n 5; 16%) than in patients without CTD (n 12;
5%; P  .02, 2 test).
Operative results. The mean estimated blood loss for
all cases was 12  1 L, with intraoperative transfusion of
14 1 units of packed red blood cells, 3 0.2 L cell saver,
19  1 units of fresh frozen plasma, and 11  1 units of
platelets. The mean length of stay in the intensive care unit
was 9.7  0.7 days, and 4.0  0.4 days were spent in the
intermediate care unit. The total hospital length of stay was
22 2 days. Patients with CTD had greater intraoperative
blood loss than patients without CTD (Table II).
Among the entire cohort of 257 patients, four intraop-
erative deaths (1.6%) and 32 deaths (12.5%) occurred
within 30 days of operation. No intraoperative deaths and
only two (6.5%) of the perioperative deaths occurred in
patients with CTD (P  .39, Fisher exact test). In patients
with a preoperatively ruptured aneurysm, six deaths (35%)
occurred within 30 days, for a rate greater than the 30-day
mortality rate for elective repairs (11%; P  .003, 2 test).
Among the entire cohort, 19 perioperative myocardial
infarctions, four perioperative strokes, and 10 pulmonary
emboli were seen. Twenty-two patients had vocal cord
paralysis, 48 patients had delayed (1 week) ventilator
weaning, with 36 needing tracheostomy, and eight patients
had subdural hematomas. Thirty-five patients (14%) had
postoperative renal failure, including nine patients with
preoperative renal insufficiency and six patients with preop-
erative renal failure. No difference was seen in the rate of
these complications among patients with and without CTD
(Table II).
Among all 257 patients, neuromuscular deficits (any
paraparesis) occurred in 31 patients (12.1%). Although the
incidence rate was higher in patients with CTD (12.9%)
compared with those without CTD (9.7%), this increase
was not statistically significant with univariate analysis (P
.58, 2 test). Permanent paraplegia occurred in only 14
Table II. Comparison of operative and postoperative
parameters and perioperative complications between
patients with and without CTD
CTD No CTD P value
No. of Crawford patches 2.1  0.2 1.7  0.1 .10
No. of bypass grafts 0.7  0.2 0.4  0.1 .01
Intercostal revascularization 15 (48%) 90 (40%) .44
Estimated blood loss (L) 18  2 11  1 .01
PRBC transfusion (U) 18  3 14  1 .16
Cell-saver transfusion (L) 5  1 3  0.2 .003
FFP transfusion (U) 23  4 18  1 .37
Platelet transfusion (U) 10  2 11  1 .19
ICU length of stay (d) 6.4  0.8 10.1  0.8 .22
Intermediate care length
of stay (d)
2.0  0.3 4.5  0.5 .12
Hospital length of stay (d) 14  1 23  2 .22
Paraparesis 4 (12.9%) 22 (9.7%) .58
Permanent paraplegia 2 (6.5%) 12 (5.3%) .68
Myocardial infarction 2 (6%) 17 (8%) .99
Renal failure 4 (13%) 31 (14%) .99
Pulmonary embolism 0 10 (4%) .61
Stroke 0 4 (2%) .99
Vocal cord paralysis 1 (3%) 21 (10%) .49
Prolonged ventilation 3 (10%) 45 (20%) .22
Tracheostomy 1 (3%) 35 (15%) .09
Subdural hematoma 2 (6%) 6 (3%) .25
PRBC, Packed red blood cells; FFP, fresh frozen plasma; ICU, intensive care
unit.
Table III. Multivariable analysis of risk factors that




Age .70 1.01 0.96-1.07
Race .38 2.22 0.37-13.47
Gender .91 0.94 0.27-3.22
Hypertension .99 1.00 0.01-99.99
COPD .23 2.30 0.59-8.96
CTD .03 9.32 1.24-70.03
Previous aortic dissection .81 1.20 0.29-5.03
Crawford extent (I, II) .23 2.27 0.59-8.75
Preoperative ruptured aneurysm .84 1.29 0.11-15.42
Preoperative renal insufficiency .39 2.37 0.33-17.07
Preoperative renal failure .30 4.17 0.28-62.58




Intercostal artery revascularized .15 2.44 0.72-8.29
Lumbar drain .008 0.16 0.04-0.62
Postoperative renal failure .60 0.65 0.13-3.22
COPD, Chronic obstructive pulmonary disease.
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patients among the entire group (5.4%) and also did not
vary with or without the presence of CTD (6.5% versus
5.3%; P  .68, Fisher exact test). However, multiple logis-
tic regression revealed that the presence of CTD was the
only factor predictive of any paraparesis (P  .03; odds
ratio, 9.3), whereas the usage of a lumbar drain was the only
factor predictive of decreased incidence of paraparesis (P
.008; odds ratio, 6.1 fold decrease; Table III). Similar
analysis of factors predictive of permanent paraplegia was
too small to achieve statistical significance (data not
shown).
Long-term results. The mean length of follow-up
was 27 months (range, 0 to 106 months), and follow-up
was complete in 244 patients (95%). The cumulative sur-
vival rate was 53.4% 4.4% at 5 years (Kaplan-Meier; Fig 1,
A), and no difference was seen among patients with or
without CTD (P  .16, log-rank test; Fig 1, B) or among
different Crawford extents (P  .29, log-rank test; Fig 1,
C). Patients with either an extent I or II aneurysm had
similar 5-year cumulative survival rates compared with pa-
tients with an extent III or IV aneurysm (51.5%  5.1%
versus 58.2% 8.5%; P .50, log-rank test). Postoperative
renal failure was associated with a decreased 5-year survival
rate (39.8%  17.2% versus 55.4%  4.6%; P  .004,
log-rank test; Fig 1, D). Presence of a preoperatively rup-
tured TAAA diminished early (30 days) (58.8%  11.9%
versus 86.0%  2.3%; P  .03, Breslow-Gehan-Wilcoxon
test) but not late (5 years) (50.4% 12.9% versus 53.3%
4.7%; P  .34, log-rank test) survival rates (Fig 1, E).
Of the two late (6 months) deaths in patients with
CTD, none were from aortic aneurysm rupture or dissec-
tion, compared with two of 31 late deaths in patients
without CTD; one death in a patient with CTD was from
rupture of a small unrepaired iliac aneurysm. Multivariable
analysis confirmed that age (P  .04) and postoperative
renal failure (P  .03) predicted late outcome, but neither
preoperative rupture (P  .17), CTD (P  .93), nor
Crawford classification (P  .21) predicted late mortality
(Table IV).
Among late survivors, no mean difference was seen in
largest aortic diameter in patients with or without CTD
(4.7  0.3 cm versus 4.4  0.3 cm; P  .47, Mann-
Whitney U test). Also, no difference was seen in the mean
size of the unrepaired proximal thoracic segment in patients
who originally had an extent III or IV TAAA (4.8 1.3 cm
with CTD versus 5.0  0.4 cm without CTD; P  .75).
Long-term freedom from recurrent aortic events was cal-
culated with death, aortic rupture, aortic dissection, or
recurrent aneurysm as endpoints and was 47.5%  4.6% at
5 years (Kaplan-Meier; Fig 2, A). This long-term graft
stability was similar in patients with or without CTD (P 
.10, log-rank test; Fig 2, B).
DISCUSSION
We show that patients with CTD have similar periop-
erative and long-term survival rates after TAAA repair com-
pared with patients without CTD. However, patients with
CTD had a greater incidence rate of extent I and II aneu-
rysms and a nine-fold increased risk of paraparesis. Use of a
lumbar drain was six-fold protective against the occurrence
of paraparesis. The early survival rate was diminished in
patients with a ruptured TAAA, and the late survival rate
was diminished in patients with postoperative renal failure.
Finally, long-term CT scan surveillance showed no relative
increase in aortic size, and persistent freedom from recur-
rent aortic events, in patients with CTD.
The long-term results of TAAA repair continue to
reaffirm the utility of surgical repair, and the Crawford
technique in particular.25 In our series, the cumulative
5-year survival rate was 53% and no difference was seen
among patients with the more extensive Crawford extent I
and II aneurysms. Our inability to detect a difference in
survival among patients with greater aneurysm extent is
similar to the observations of some series5 but not oth-
ers.2,7,26 Our small sample size, and especially our relatively
few number of extent IV aneurysms, with their superior
survival rate4 may be insufficiently powered to detect a
difference from aneurysm extent. However, we were able to
detect a significant decrease in perioperative survival rate
among patients with a ruptured TAAA (Fig 1, E) or with
postoperative renal failure (Fig 1, D), as noted by oth-
ers.2,7,26 Our data also suggest that the long-term survival
rate after TAAA repair performed for aneurysm rupture is
similar to that of the rest of the electively performed cohort
among survivors beyond the perioperative period, similar
to that suggested by some series examining survivors of
ruptured infrarenal aortic aneurysms.27-29
Patients with CTD had similar long-term survival rates
after TAAA repair in this series compared with patients
without CTD (Fig 1, B). Although this finding may have
been anticipated in this group of younger patients with
fewer associated comorbid diseases, we believe that this
information is unexpected. Life expectancy in patients with
Table IV. Multivariable analysis of risk factors that




Age .04 1.03 1.00-1.07
Gender .24 0.69 0.37-1.29
Race .47 0.70 0.27-1.83
Hypertension .43 1.48 0.56-3.92
Coronary artery disease .34 0.74 0.40-1.37
Peripheral vascular disease .83 1.08 0.55-2.12
COPD .28 0.70 0.36-1.35
CTD .93 0.94 0.25-3.59
Crawford extent (I, II) .21 0.64 0.32-1.28
Preoperative ruptured aneurysm .17 0.50 0.18-1.35
Preoperative renal insufficiency .24 0.54 0.19-1.53
Preoperative renal failure .44 1.85 0.39-8.75
Lumbar drain .81 1.09 0.55-2.19
Postoperative renal failure .03 0.40 0.17-0.90
Paraparesis .58 1.58 0.32-7.84
Permanent paraplegia .11 0.23 0.04-1.38
COPD, Chronic obstructive pulmonary disease.
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Fig 1. A, Kaplan-Meier plot of cumulative survival rate of 257 patients followed after TAAA repair. Time is in months.
B, Kaplan-Meier plots of cumulative survival rate after TAAA repair in patients with (Œ) and without () CTD. C,
Kaplan-Meier plots of cumulative survival rate after TAAA repair stratified by Crawford extent (I,; II,; III,; IV,
). D, Kaplan-Meier plots of cumulative survival rate after TAAA repair in patients with (f) and without ()
postoperative renal failure. E, Kaplan-Meier plots of cumulative survival rate after TAAA repair in patients with (f) and
without () preoperative ruptured aneurysm.
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CTD is reduced compared with the population.13 Al-
though several series have reported excellent survival rates
in patients with CTD after aortic repair, it is unclear with
what this rate is compared.17,19,20 In addition, these series
included cardiac and ascending aortic repairs that may
result in improved outcome. We note, however, that the
small number of patients with CTD, especially in longer
term follow-up, may not allow us to exclude a type II error
(ie, that patients with CTD have reduced survival rates after
TAAA repair).
Furthermore, our finding that patients with CTD have
long-term aortic stability after repair, as reflected by lack of
additional aortic dilation, aneurysm formation, dissection,
or rupture (Fig 2, B), was not anticipated; leaving behind
any area of unrepaired aorta places the patient at continued
risk of aneurysmal expansion and rupture.30 This observa-
tion explains our higher frequency of placement of a bypass
graft to the left renal artery in patients with CTD, minimiz-
ing visceral patch size (Table II).30 Our high percentage of
extent I and II aneurysms, however, suggests that our
patients have their entire aorta, previously at risk, repaired
and thus are unlikely to have a subsequent event. In addi-
tion, it is unclear whether or not patients with progression
to aneurysmal stage have a different subsequent event rate
compared with patients with chronic dissection alone; pa-
tients with aortic tailoring or fenestration procedures for
dissection alone, without aneurysm, were excluded from
this report.
A previous report from our institution suggested that
35% of patients with Marfan syndrome had evidence on
magnetic resonance imaging of progressive dilation of the
thoracoabdominal aorta within a mean of 5 years after
composite repair of the aortic root.31 This evidence of
aortic instability in a large percentage of patients with CTD
underscores the need to image the thoracoabdominal aorta
and potentially repair it; lack of additional events after
TAAA repair, as reported here, confirms the efficacy of the
repair. On the other hand, our sample size may be too small
to detect the 35% of long-term survivors who do have
progressive aortic dilation. In addition, our follow-up with
CT scan may not be as sensitive for events as is magnetic
resonance imaging. However, we believe that the previ-
ously reported large incidence rate of thoracoabdominal
aortic dilation is present only in patients with only the
ascending aorta replaced and, therefore, at an earlier stage
of the cardiovascular disease.17,19-20 Because after repair of
an extent I or II aneurysm all native proximal thoracoab-
dominal aorta other than the visceral patches is obliterated,
no aorta is left that can undergo progressive dilation (Fig 2,
A).
In our series, paraparesis and permanent paraplegia
occurred in 12.9% and 6.5%, respectively, of patients with
CTD, a rate similar to that previously reported.2,17 Our
inclusion of patients with CTD other than Marfan syn-
drome may possibly slightly elevate our neurologic event
rate above other reports,32 although the differences in these
small groups are unlikely to be significant. However, pa-
tients with CTD were more likely to have paraparesis than
patients without CTD (Table III). This increase may be
due to the increased prevalence of extent I and II aneu-
rysms in patients with CTD.2,7,32-35 Also unknown is
whether some of these patients have their spinal arteries
obliterated with dissection as a consequence of the opera-
tive procedure, but the significance of this possibility is
unclear. Nonetheless, the protective effect of lumbar drain-
age36-39 was reaffirmed even in this high-risk group of
patients (Table III). This suggests that paraparesis in pa-
tients with CTD is likely to be the result of a multifactorial
process, reflecting a relative balance of factors maintaining
spinal cord perfusion,40 rather than simple extent of the
aneurysm and interruption of a single spinal artery.7,35
Fig 2. A, Kaplan-Meier plot of cumulative graft freedom from additional degeneration in 257 patients followed after
TAAA repair. Time is in months. B, Kaplan-Meier plots of cumulative graft freedom from additional degeneration after
TAAA repair in patients with (Œ) and without () CTD.
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The durability of TAAA repair in patients with CTD
may reflect surgical replacement of defective structural ele-
ments, such as fibrillin or collagen, limited to the aorta.12,23
Whether a different distribution of fibrillin exists in the
aortic branches compared with the aorta and whether this
may be the case only in subsets of patients are not known.
Continued postprocedural surveillance is, therefore, vital to
detect potential events in the extreme (10 year) long-
term follow-up.
We reaffirm that outcome after TAAA repair is durable,
with reasonable cumulative 5-year survival, low risk of
postoperative paraplegia, and long-term aortic stability ex-
pected for most patients. Patients with CTD can expect
their outcome after TAAA repair, including long-term sur-
vival and aortic stability, to be similar to patients without
CTD who undergo TAAA repair. We advocate early elec-
tive TAAA repair in patients with CTD because of the
safety, efficacy, and durability of the procedure. Early elec-
tive repair also allows placement of a lumbar CSF drain that
helps protect against the higher incidence of paraparesis in
these patients.
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THE PACIFIC VASCULAR RESEARCH FOUNDATION
IS ACCEPTING APPLICATIONS
FOR THE
2003 WYLIE SCHOLAR AWARD IN ACADEMIC VASCULAR SURGERY
The Wylie Scholar Award was established by the Pacific Vascular Research Foundation to
honor the legacy of Edwin J. Wylie by providing research support to outstanding vascular
surgeon-scientists.
Purpose
The Award is intended to enhance the career development of academic vascular surgeons
with an established research program in vascular disease. The award consists of a grant in
the amount of $50,000 per year for three years. Funding for the second and third years is
subject to review of acceptable progress reports. This three-year award is nonrenewable
and may be used for research support, essential expenses, or other academic purposes at
the discretion of the Scholar and the medical institution. The award may not be used for
any indirect costs.
Eligibility
The candidate must be a vascular surgeon who has completed an accredited residency in
general surgery and who holds a full-time appointment at a medical school accredited by
the Liaison Committee on Medical Educators in the United States or the Committee for
the Accreditation of Canadian Medical Schools in Canada.
How to Apply
The applications are due by February 1, 2003, for the award to be granted July 1, 2003.
Applications may be obtained by writing to: Pacific Vascular Research Foundation, Wylie
Scholar Award, 3627 Sacramento Street, San Francisco, CA 94118.
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